V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Pacific BioSciences of California Executive Compensation (FY25)

PACB · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Christian Henry
Latest say-on-pay support
=
June 3, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Pacific BioSciences of California brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (EX-10): August 5, 2026
11 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Pacific BioSciences of California brief$1,500Get the executive brief
Velarion Member, one year
197 figures on this page: 191 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christian Henry: $9,181,620 → $4,309,846 (53.1% lower)
Say-on-pay support: 60.4% → 83.1% (22.7 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Pacific BioSciences of California's chief executive and what were they paid?
Christian Henry was paid $4,309,846 in total compensation as President and Chief Executive Officer for fiscal 2025. Compared with the $9,181,620 reported for fiscal 2024, Henry's total was 53.1% lower.
What was Pacific BioSciences of California's say-on-pay result?
The say-on-pay proposal drew 83.1% of votes cast including abstentions in favor at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in Pacific BioSciences of California's peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., AbCellera Biologics Inc., Adaptive Biotechnologies Corporation, Azenta, Inc. and Castle Biosciences, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christian Henry
President, Chief Executive Officer
◇—◇◇◇—◇◇
Mark Oene
Chief Operating Officer
◇—◇◇◇—◇◇
Jeff Eidel
Chief Commercial Officer
◇◇◇◇◇——◇
Peter Fromen
Former Chief Commercial Officer
Departed during or after this year
◇—◇◇——◇◇
Susan Kim
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christian Henry
President and Chief Executive Officer
◇—◇—◇—◇◇
Mark Van Oene
Chief Operating Officer
◇—◇—◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christian Henry
President and Chief Executive Officer
◇—◇—◇——◇
Mark Van Oene
Chief Operating Officer
◇—◇—◇——◇
Jeff Eidel
Former Chief Commercial Officer
Departed during or after this year
◇—◇———◇◇
Susan Kim
Former Chief Financial Officer
Departed during or after this year
◇—◇————◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christian Henry
President and Chief Executive Officer
◇—◇◇◇——◇
Jim Gibson
Chief Financial Officer
◇—◇◇◇——◇
Mark Van Oene
Chief Operating Officer
◇—◇◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christian O. HenryOptions/SARs◇——◇—◇◇
Christian O. HenryRSU◇——◇——◇
Jim R. GibsonOptions/SARs◇——◇—◇◇
Jim R. GibsonRSU◇——◇——◇
Jim R. GibsonOptions/SARs◇——◇—◇◇
Mark Van OeneRSU◇——◇——◇
Mark Van OeneOptions/SARs◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jim GibsonOption◇—◇3/31/2035
PSU◇◇——
Option◇—◇3/31/2035
Mark OenePSU◇◇——
PSU◇◇——
PSU◇◇——
PSU◇◇——
Option◇—◇3/2/2032
PSU◇◇——
PSU◇◇——
Option◇—◇3/19/2035
Christian HenryPSU◇◇——
Option◇—◇3/19/2035
PSU◇◇——
PSU◇◇——
Option◇—◇3/2/2032
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Christian Henry
President and Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance base◇
Severance cash amount◇
Mark Van Oene
Chief Operating Officer · Terms as announced by the company
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Change-in-control base◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher M. Smith
◇◇◇———◇
John F. Milligan, Ph.D
Board chair
◇—◇———◇
Marshall Mohr
◇—◇———◇
William Ericson
◇—◇———◇
Kathy Ordoñez
◇—◇———◇
Randy Livingston
◇—◇———◇
Lucy Shapiro, Ph.D
◇—◇———◇
Hannah A. Valantine, M.D
◇—◇———◇
David Meline
◇—————◇
Christian O. Henry and Chris Gibson, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • 10x Genomics, Inc. TXG
  • AbCellera Biologics Inc. ABCL
  • Adaptive Biotechnologies Corporation ADPT
  • Azenta, Inc. AZTA
  • Castle Biosciences, Inc. CSTL
  • Cytek Biosciences, Inc. CTKB
  • Fulgent Genetics, Inc. FLGT
  • Ginkgo Bioworks, Inc. DNA
  • Guardant Health, Inc. GH
  • Myriad Genetics, Inc. MYGN
  • NeoGenomics, Inc. NEO
  • Quanterix Corporation QTRX
  • Repligen Corporation RGEN
  • Twist Bioscience Corporation TWST
  • Veracyte, Inc. VCYT

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 3, 2026=◇◇◇
2024June 4, 2025=◇◇◇
2023June 18, 2024=◇◇◇
2022May 24, 2023=◇◇◇
2019August 4, 2020=◇◇◇
2016May 24, 2017=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Christian Henry (President and Chief Executive Officer), FY2025 total compensation $4,309,846 (base salary $748,250) [exec_comp, SEC accession 0001299130-26-000064, filed 2026-04-23]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Pacific BioSciences of California files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Pacific BioSciences of California disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pacific BioSciences of California sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Pacific BioSciences of California's disclosed peer group is defensible, who names Pacific BioSciences of California back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
197 figures on this page: 191 cited to the filing that reported them, 6 calculated from figures it prints.
191 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001299130-26-000117
    Exhibit
  2. 0001299130-26-000092
    Item 5.07 Submission of Matters to a Vote of Security Holders
  3. 0001299130-26-000064
    Compensation Discussion and Analysis · Director Compensation · Director Compensation for Fiscal Year 2025 · Outstanding Equity Awards at Fiscal Year-End 2025 · and 3 more sections
  4. 0001299130-25-000140
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001299130-25-000090
    Executive Compensation Tables · Summary Compensation Table for Fiscal Years 2024, 2023 and 2022
  6. 0001299130-24-000146
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001299130-24-000097
    Summary Compensation Table for Fiscal Years 2023, 2022 and 2021
  8. 0001299130-23-000070
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001104659-23-045011
    Executive Compensation Tables
  10. 0001299130-20-000116
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001299130-17-000040
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pacific BioSciences of California executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PACB (accessed 2026).
Short form: data: Velarion

The Pacific BioSciences of California brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
11 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pacific BioSciences of California and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Pacific BioSciences of California discloses

The companies named in PACB's own disclosed peer group.

10x Genomics, Inc.AbCellera Biologics Inc.Adaptive Biotechnologies CorporationAzenta, Inc.Castle Biosciences, Inc.Cytek Biosciences, Inc.Fulgent Genetics, Inc.Ginkgo Bioworks, Inc.Guardant Health, Inc.Myriad Genetics, Inc.NeoGenomics, Inc.Quanterix CorporationRepligen CorporationTwist Bioscience CorporationVeracyte, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy